Aggiornamento
La sindrome di Kawasaki nel 2013: casi clinici e novità
Kawasaki disease 2013: clinical cases and new issues
Teresa Giani1, Gabriele Simonini1, Gaia Vannucci1, Davide Moretti1, Ilaria Pagnini1, Edoardo Marrani1, Giovanni Battista Calabri2, Rolando Cimaz1
1Servizio di Reumatologia Pediatrica, 2Servizio di Cardiologia Pediatrica, Azienda Ospedaliero-Universitaria “Anna Meyer”, Firenze
Giugno 2013 - pagg. 359 -366
Abstract
Kawasaki disease is one of the most common vasculitis in childhood. The typical expression
of Kawasaki disease is characterized by persistent fever for at least five
days, polymorphous rash, bilateral non-exudative conjunctivitis, changes in the lips
and oral mucosa, perianal hyperemia, extremity changes, and lymphadenopathy.
Although this is an acute vasculitis with self-limited course, 15-25% of untreated cases
can develop coronary artery aneurysms or ectasia. The diagnosis can be complicated
due to the lack of pathognomonic signs and laboratory markers and the incomplete
or atypical expressions in which this disease may manifest. This article
provides a summary of the main differential diagnoses and the guidelines for the
management of the incomplete forms.
Parole chiave
Suggerite dall'AI
Classificazione MeSH
Contenuto riservato
Per leggere l'articolo completo è necessario effettuare il login.
Non sei ancora registrato? Registrati
Bibliografia
1. Uehara R, Belay ED. Epidemiology of
Kawasaki disease in Asia, Europe, and the
United States. J Epidemiol 2012;22:79-85.
2. Rowley AH, Baker SC, Shulman ST, et al. Ultrastructural,
immunofluorescence, and RNA
evidence support the hypothesis of a “new”
virus associated with Kawasaki disease. J Infect
Dis 2011;203:1021-30.
3. Suenaga T, Suzuki H, Shibuta S, Takeuchi T,
Yoshikawa N. Detection of Multiple Superantigen
Genes in Stools of Patients with Kawasaki
Disease. J Pediatr 2009;155:266-70.
4. Onouchi Y. Genetics of Kawasaki disease:
what we know and don’t know. Circ J 2012;76:
1581-6.
5. Yeung RS. Kawasaki disease: update on
pathogenesis. Curr Opin Rheumatol 2010;22:
551-60.
6. Harnden A, Takahashi M, Burgner D.
Kawasaki disease. BMJ 2009;338:b1514.
7. Burns JC, Mason WH, Glode MP, et al. Clinical
and epidemiologic characteristics of patients
referred for evaluation of possible
Kawasaki disease. United States Multicenter
Kawasaki Disease Study Group. J Pediatr 1991;
118:680-6.
8. Komatsu H, Tateno A. Failure to distinguish
systemic-onset juvenile idiopathic arthritis
from incomplete Kawasaki disease in an infant.
J Paediatr Child Health 2007;43:707-9.
9. Newburger JW, Takahashi M, Gerber MA,
et al. Diagnosis, treatment, and long-term management
of Kawasaki disease: a statement for
health professionals from the Committee on
Rheumatic Fever, Endocarditis, and Kawasaki
Disease, Council on Cardiovascular Disease in
the Young, American Heart Association. Pediatrics
2004;114:1708-33.
10. Yeo Y, Kim T, Ha K, et al. Incomplete
Kawasaki disease in patients younger than 1
year of age: a possible inherent risk factor. Eur
J Pediatr 2009;168:157-62.
11. Fukushige J, Takahashi N, Ueda Y, Ueda K.
Incidence and clinical features of incomplete
Kawasaki disease. Acta Paediatr 1994;83:1057-
60.
12. Lin YL, Chang TJ, Lu KC, Hu WL, Ke TY.
MESSAGGI CHIAVE
! L’incidenza della sindrome di Kawasaki
(SK) al di sotto dei 5 anni di età è
pari a: 240 casi/100.000 in Giappone,
15-25/100.000 negli Stati Uniti e
in Canada, 5-10/100.000 in Europa.
! Nelle forme atipiche di SK i segni
classici di malattia possono accompagnarsi
o essere dominati da manifestazioni
inusuali: gastrointestinali (vomito,
diarrea, idrope della colecisti, epatocolangite),
neurologiche (convulsioni,
stroke), oculari (uveite), polmonari (infiltrati
polmonari, versamento pleurico),
muscolo-scheletriche (artralgie, artrite).
! Gli elementi di laboratorio a supporto
del sospetto di SK sono gli indici
di flogosi elevati, la leucocitosi, la piastrinosi,
l’ipoalbuminemia, l’ipertransaminasemia,
la piuria sterile.
! Circa il 25% dei pazienti non trattati
sviluppa un danno alle coronarie. La
percentuale si riduce al 3-5% nei soggetti
che abbiano ricevuto l’infusione di
immunoglobuline per via ev (IVIG) e l’acido
acetilsalicilico (ASA).
! Il 15-20% dei soggetti trattati è resistente
al trattamento con ripresa della
febbre a distanza di 24-48 ore dal termine
dell’infusione.
! In questi casi la strada terapeutica
più comunemente percorsa è quella di
una seconda dose di IVIG, anche se un
terzo dei casi rimane febbrile anche dopo
il secondo ciclo.
! I corticosteroidi stanno assumendo
un ruolo sempre più “evidence based”
come farmaci di prima linea in associazione
alle IVIG, potenziandone l’effetto
protettivo nella riduzione del rischio
di lesioni coronariche.
! Un sistema di scoring adattabile a
tutte le popolazioni potrebbe permettere
di selezionare i pazienti a maggiore
rischio di resistenza alle IVIG, riservando
loro una terapia più aggressiva fin
dalle fasi iniziali.
Surgical treatment of Kawasaki disease with intestinal
pseudo-obstruction. Indian J Pediatr
2011;78:237-9.
13. Zulian F, Falcini F, Zancan L, et al. Acute
surgical abdomen as presenting manifestation
of Kawasaki disease. J Pediatr 2003;142:731-5.
14. Kanegaye JT, Wilder MS, Molkara D, et al.
Recognition of a Kawasaki disease shock syndrome.
Pediatrics 2009;123:783-9.
15. Ganesh R, Srividhya VS, Vasanthi T, Shivbalan
S. Kawasaki disease mimicking retropharyngeal
abscess. Yonsei Med J 2010;51:
784-6.
16. Bosch Marcet J, Serres Creixams X, Penas
Boira M, Inaraja Martinez L. Mediastinal lymphadenopathy:
a variant of incomplete Kawasaki
disease. Acta Paediatr 1998;87:1200-2.
17. Falcini F, Simonini G, Calabri GB, Cimaz R.
Multifocal lymphadenopathy associated with
severe Kawasaki disease: a difficult diagnosis.
Ann Rheum Dis 2003;62:688-9.
18. Runel-Belliard C, Lasserre S, Quinet B,
Grimprel E. Febrile torticollis: an atypical presentation
of Kawasaki disease. Arch Pediatr
2009;16:115-7.
19. Duzova A, Topaloglu R, Keskin M, Ozcelik
U, Secmeer G, Tokgozoglu AM. An unusual
pattern of arthritis in a child with Kawasaki
syndrome. Clin Rheumatol 2004;23:73-5.
20. Jen M, Brucia LA, Pollock AN, Burnham
JM. Cervical spine and temporomandibular
joint arthritis in a child with Kawasaki disease.
Pediatrics 2006;118:e1569-71.
21. Sengler C, Gaedicke G, Wahn U, Keitzer R.
Pulmonary symptoms in Kawasaki disease. Pediatr
Infect Dis J 2004;23:782-4.
22. Kuniyuki S, Asada M. An ulcerated lesion at
the BCG vaccination site during the course of
Kawasaki disease. J Am Acad Dermatol 1997;
37:303-4.
23. Luca NJ, Yeung RS. Epidemiology and management
of Kawasaki disease. Drugs 2012;72:
1029-38.
24. Ravelli A, Grom AA, Behrens EM, Cron RQ.
Macrophage activation syndrome as part of
systemic juvenile idiopathic arthritis: diagnosis,
genetics, pathophysiology and treatment.
Genes Immun 2012;13:289-98.
25. Simonini G, Pagnini I, Innocenti L, Calabri
GB, De Martino M, Cimaz R. Macrophage activation
syndrome/Hemophagocytic Lymphohistiocytosis
and Kawasaki disease. Pediatr
Blood Cancer 2010;55:592.
26. Tanaka N, Naoe S, Masuda H, Ueno T.
Pathological study of sequelae of Kawasaki disease
(MCLS) with special reference to the
heart and coronary arterial lesions. Acta
Pathol Jpn 1986;36:1513-27.
27. Muta H, Ishii M, Egami K, et al. Early intravenous
gamma-globulin treatment for
Kawasaki disease: the nationwide surveys in
Japan. J Pediatr 2004;144:496-9.
28. Tremoulet AH, Best BM, Song S, et al. Resistance
to intravenous immunoglobulin in
children with Kawasaki disease. Pediatr 2008;
153:117-21.
29. Burns JC, Capparelli EV, Brown JA, Newburger
JW, Glode MP. Intravenous gamma
globulin treatment and retreatment in Kawasaki
disease. US/Canadian Kawasaki Syndrome
Study Group. Pediatr Infect Dis J 1998;17:1144-
8.
30. Uehara R, Belay ED, Maddox RA, et al.
Analysis of potential risk factors associated
with nonresponse to initial intravenous immunoglobulin
treatment among Kawasaki disease
patients in Japan. Pediatr Infect Dis J 2008;
27:155-60.
31. Rowley AH, Shulman ST. Pathogenesis and
management of Kawasaki disease. Expert Rev
Anti Infect Ther 2010;8:197-203.
32. Blaisdell LL, Hayman JA, Moran AM. Infliximab
treatment for pediatric refractory
Kawasaki disease. Pediatr Cardiol 2011;32:
1023-7.
33. Suzuki H, Terai M, Hamada H, et al. Cyclosporin
A treatment for Kawasaki disease refractory
to initial and additional intravenous immunoglobulin.
Pediatr Infect Dis J 2011;30:
871-6.
34. Miura M, Ohki H, Yoshiba S, et al. Adverse
effects of methylprednisolone pulse therapy in
refractory Kawasaki disease. Arch Dis Child
2005;90:1096-7.
35. Pentikäinen PJ. Pharmacological aspects of
corticosteroid pulse therapy. Scand J Rheumatol
Suppl 1984;54:6-9.
36. Makata H, Ichiyama T, Uchi R, et al. Anti-inflammatory
effect of intravenous immunoglobulin
in comparison with dexamethasone in
vitro: implication for treatment of Kawasaki disease.
Arch Pharmacol 2006;373:325-32.
37. Brown TJ, Crawford SE, Cornwall ML, Garcia
F, Shulman ST, Rowley AH. CD8 T lymphocytes
and macrophages infiltrate coronary
artery aneurysms in acute Kawasaki disease. J
Infect Dis 2001;184:940-3.
38. Newburger JW, Sleeper LA, McCrindle BW,
et al.; Pediatric Heart Network Investigators.
Randomized trial of pulsed corticosteroid therapy
for primary treatment of Kawasaki disease.
N Engl J Med 2007;356:663-75.
39. Ogata S, Ogihara Y, Honda T, Kon S, Akiyama
K, Ishii M. Corticosteroid pulse combination
therapy for refractory Kawasaki disease: a
randomized trial. Pediatrics 2012;129:17-23.
40. Kobayashi T, Saji T, Otani T, et al.; RAISE
Study Group investigators. Efficacy of immunoglobulin
plus prednisolone for prevention
of coronary artery abnormalities in severe
Kawasaki disease (RAISE Study): a randomised,
open-label, blinded-endpoints trial.
Lancet 2012;379:1613-20.
41. Kobayashi T, Inoue Y, Takeuchi K, et al.
Prediction of intravenous immunoglobulin unresponsiveness
in patients with Kawasaki disease.
Circulation 2006;113:2606-12.
42. Burns JC, Best BM, Mejias A, et al. Infliximab
treatment of intravenous immunoglobulin-
resistant Kawasaki disease. J Pediatr 2008;
153:833-8.
43. Burns JC, Mason WH, Hauger SB, et al. Infliximab
treatment for refractory Kawasaki syndrome.
J Pediatr 2005;146:662-7.
44. Portman MA, Olson A, Soriano B, Dahdah
N, Williams R, Kirkpatrick E. Etanercept as adjunctive
treatment for acute Kawasaki disease:
study design and rationale. Am Heart J 2011;
161:494-9.
45. Choueiter NF, Olson AK, Shen DD, Portman
MA. Prospective open-label trial of Etanercept
as adjunctive therapy for Kawasaki disease.
J Pediatr 2010;157:960-6.
46. Lee Y, Schulte DJ, Shimada K, et al. Interleukin-
1! is crucial for the induction of coronary
artery inflammation in a mouse model of
Kawasaki disease. Circulation 2012;125:1542-
50.
47. Cohen S, Tacke CE, Straver B, Meijer N,
Kuipers IM, Kuijpers TW. A child with severe
relapsing Kawasaki disease rescued by IL-1 receptor
blockade and extracorporeal membrane
oxygenation. Ann Rheum Dis 2012;71:2059-61.
Corrispondenza: t.giani@meyer.it